AbbVie Inc. (ABBV) Stock: Rise as Q3 Revenue Jumps 10.3% and EPS Tops $3.82

TLDR

• AbbVie stock gains 1.72% as third-quarter revenue climbs 10.3% to $17.4 billion.
• AbbVie reports adjusted EPS of $3.82 as earnings more than double year over year.
• Skyrizi and Rinvoq drive immunology revenue growth as Humira sales decline 31.2%.
• AbbVie raises its 2026 adjusted EPS guidance to a range of 13.95–13.99 per share.
• AbbVie announces a 5.2% dividend increase, with higher payments starting in February 2027.

AbbVie Inc. (NYSE: ABBV) shares advanced 1.72% to $295.79 after the pharmaceutical company reported strong third-quarter results. The stock gained $4.99 as revenue growth and higher earnings supported its performance. Meanwhile, the company raised its full-year 2026 earnings guidance and announced a dividend increase.

AbbVie Inc., ABBV

AbbVie reported third-quarter revenue of $17.404 billion, representing 10.3% growth from the previous year. Operational revenue increased 10.5%, reflecting stronger demand across its major pharmaceutical businesses. Additionally, adjusted diluted earnings per share reached $3.82, while GAAP diluted EPS stood at $2.37.

The results highlighted continued growth across immunology and neuroscience, alongside weaker performance in aesthetics. Furthermore, AbbVie completed its acquisition of Apogee Therapeutics to strengthen its immunology development pipeline. The company also increased its 2026 earnings outlook and announced higher shareholder distributions.

AbbVie Q3 Revenue Growth Driven by Immunology and Neuroscience

AbbVie’s immunology portfolio generated $9.165 billion in third-quarter revenue, increasing 16.3% year over year. Skyrizi contributed $5.776 billion, representing 22.7% growth on a reported basis. Meanwhile, Rinvoq generated $2.706 billion, marking a 23.9% increase during the quarter.

Humira revenue declined 31.2% to $683 million as competition continued affecting its sales. The combined performance of Skyrizi and Rinvoq supported overall immunology growth. Their revenue contributions also highlighted the portfolio’s changing composition following Humira’s declining sales.

The neuroscience division generated $3.389 billion, representing 19.4% annual growth. Vraylar revenue increased 14.3% to $1.068 billion, while Botox Therapeutic sales reached $1.080 billion. Additionally, Ubrelvy generated $449 million, and Qulipta contributed $398 million during the quarter.

Qulipta recorded 38.2% reported revenue growth, making it one of the portfolio’s strongest performers. Meanwhile, Vyalev generated $286 million as AbbVie expanded its neuroscience business. These results demonstrated broad growth across several treatments within the division.

Oncology and Aesthetics Deliver Mixed Third-Quarter Results

AbbVie’s oncology portfolio generated $1.696 billion in third-quarter revenue, increasing 0.8% year over year. Venclexta revenue rose 10.7% to $803 million, while Elahere increased 31% to $224 million. However, Imbruvica revenue declined 26.1% to $522 million, limiting the division’s overall growth.

The aesthetics portfolio recorded $1.176 billion in revenue, representing a 1.4% annual decline. Botox Cosmetic generated $669 million, increasing 4.9% compared with the previous year. In contrast, Juvederm revenue fell 11.9% to $222 million during the quarter.

AbbVie reported a GAAP gross margin of 75.4%, while its adjusted gross margin reached 85.1%. Selling, general and administrative expenses represented 23.5% of revenue on a GAAP basis. Additionally, adjusted operating margin reached 48.7%, compared with 36% under GAAP accounting.

AbbVie Raises 2026 Guidance and Announces Dividend Increase

Following its third-quarter performance, AbbVie increased its full-year 2026 adjusted diluted EPS guidance. The company raised its forecast from $13.76–$13.96 to $13.95–$13.99 per share. The updated range includes a $0.69 per-share impact from acquired research and development expenses and milestones.

AbbVie also completed its acquisition of Apogee Therapeutics during the quarter. The transaction strengthens its immunology pipeline and expands its potential treatment development opportunities. The acquisition forms part of the company’s broader strategy to support future pharmaceutical growth.

AbbVie announced a 5.2% increase in its 2027 dividend. The higher dividend will begin with the payment scheduled for February 2027. The announcement extends the company’s shareholder distribution strategy alongside its improving financial performance.

The latest results reflect continued revenue expansion across AbbVie’s major pharmaceutical businesses. Stronger immunology and neuroscience sales offset declines in selected oncology and aesthetics products. Meanwhile, higher earnings guidance and dividend growth provide further details about the company’s financial outlook.

The post AbbVie Inc. (ABBV) Stock: Rise as Q3 Revenue Jumps 10.3% and EPS Tops $3.82 appeared first on Blockonomi.